189 related articles for article (PubMed ID: 12918894)
1. Nateglinide (Starlix): update on a new antidiabetic agent.
Phillips LS; Dunning BE
Int J Clin Pract; 2003; 57(6):535-41. PubMed ID: 12918894
[TBL] [Abstract][Full Text] [Related]
2. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
Campbell IW
Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
[TBL] [Abstract][Full Text] [Related]
3. Effects of nateglinide on myocardial microvascular reactivity in Type 2 diabetes mellitus--a randomized study using positron emission tomography.
Bengel FM; Abletshauser C; Neverve J; Schnell O; Nekolla SG; Standl E; Schwaiger M
Diabet Med; 2005 Feb; 22(2):158-63. PubMed ID: 15660732
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, tolerability and safety of nateglinide in combination with metformin. Results from a study under general practice conditions.
Schatz H; Schoppel K; Lehwalder D; Schandry R
Exp Clin Endocrinol Diabetes; 2003 Aug; 111(5):262-6. PubMed ID: 12951631
[TBL] [Abstract][Full Text] [Related]
5. [symbol: see text] Nateglinide and [symbol: see text] repaglinide for type 2 diabetes?
Drug Ther Bull; 2003 Jul; 41(7):52-4. PubMed ID: 12879789
[TBL] [Abstract][Full Text] [Related]
6. Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis.
Tentolouris N; Boutati E; Karambakalis N; Perrea D; Tselepis AD; Tsoukala C; Kyriaki D; Lourida E; Anastasopoulou I; Karafoullidou A; Raptis SA; Katsilambros N
Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):6-12. PubMed ID: 15871845
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent.
McLeod JF
Clin Pharmacokinet; 2004; 43(2):97-120. PubMed ID: 14748619
[TBL] [Abstract][Full Text] [Related]
8. Meglitinide analogues in the treatment of type 2 diabetes mellitus.
Landgraf R
Drugs Aging; 2000 Nov; 17(5):411-25. PubMed ID: 11190420
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus.
Keilson L; Mather S; Walter YH; Subramanian S; McLeod JF
J Clin Endocrinol Metab; 2000 Mar; 85(3):1081-6. PubMed ID: 10720043
[TBL] [Abstract][Full Text] [Related]
10. Nateglinide therapy for type 2 diabetes mellitus.
Levien TL; Baker DE; Campbell RK; White JR
Ann Pharmacother; 2001 Nov; 35(11):1426-34. PubMed ID: 11724096
[TBL] [Abstract][Full Text] [Related]
11. Nateglinide: a new rapid-acting insulinotropic agent.
Hanif W; Kumar S
Expert Opin Pharmacother; 2001 Jun; 2(6):1027-31. PubMed ID: 11585005
[TBL] [Abstract][Full Text] [Related]
12. A review of nateglinide in the management of patients with type 2 diabetes.
Tentolouris N; Voulgari C; Katsilambros N
Vasc Health Risk Manag; 2007; 3(6):797-807. PubMed ID: 18200800
[TBL] [Abstract][Full Text] [Related]
13. [Fasting hyperglycemia and postprandial glucose peaks. Diabetes therapy mustact on 2 sides].
MMW Fortschr Med; 2003 Aug; 145(33-34):59. PubMed ID: 14526583
[No Abstract] [Full Text] [Related]
14. Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes.
Gao HW; Xie C; Wang HN; Lin YJ; Hong TP
Acta Pharmacol Sin; 2007 Apr; 28(4):534-9. PubMed ID: 17376293
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes.
Israel MK; Istvan E; Baron MA
Vasc Health Risk Manag; 2008; 4(6):1167-78. PubMed ID: 19337530
[TBL] [Abstract][Full Text] [Related]
16. Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients.
Marre M; Van Gaal L; Usadel KH; Ball M; Whatmough I; Guitard C
Diabetes Obes Metab; 2002 May; 4(3):177-86. PubMed ID: 12047396
[TBL] [Abstract][Full Text] [Related]
17. Nateglinide is useful for nonalcoholic steatohepatitis (NASH) patients with type 2 diabetes.
Morita Y; Ueno T; Sasaki N; Tateishi Y; Nagata E; Kage M; Sata M
Hepatogastroenterology; 2005; 52(65):1338-43. PubMed ID: 16201069
[TBL] [Abstract][Full Text] [Related]
18. Nateglinide.
Halas CJ
Am J Health Syst Pharm; 2001 Jul; 58(13):1200-5. PubMed ID: 11449877
[TBL] [Abstract][Full Text] [Related]
19. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
Kikuchi M
Diabet Med; 1996 Sep; 13(9 Suppl 6):S151-5. PubMed ID: 8894500
[TBL] [Abstract][Full Text] [Related]
20. Differential therapeutic effects of nateglinide and acarbose on fasting and postprandial lipid profiles: a randomized trial.
Zhou J; Deng Z; Lu J; Li H; Zhang X; Peng Y; Mo Y; Bao Y; Jia W
Diabetes Technol Ther; 2015 Apr; 17(4):229-34. PubMed ID: 25781235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]